Molecular surveillance in the nirsevimab era: lessons from respiratory syncytial virus breakthrough infections
- PMID: 39419047
- DOI: 10.1016/S1473-3099(24)00596-6
Molecular surveillance in the nirsevimab era: lessons from respiratory syncytial virus breakthrough infections
Conflict of interest statement
FM-T has acted as principal investigator in randomised controlled trials sponsored by Ablynx, Abbot, Seqirus, Sanofi Pasteur MSD, Sanofi Pasteur, Cubist, Wyeth, Merck, Pfizer, Roche, Regeneron, Jansen, Medimmune, Novavax, Novartis, and GSK, with honoraria paid to his institution. FM-T also reports relationships with GSK Vaccines, Pfizer, Sanofi Pasteur, Janssen Pharmaceuticals, MSD, and Seqirus that include consulting or advisory. NM declares no competing interests. This work was also supported by Framework Partnership Agreement between the Consellería de Sanidad de la Xunta de Galicia and GENVIP-IDIS-2021–2024 (SERGAS-IDIS March, 2021; Spain). Additionally, this work was supported by (1) Carlos III Health Institute and ReSVinext (PI16/01569), Enterogen (PI19/01090), and OMI-COVI-VAC (PI22/00406; to FM-T), cofinanced by FEDER, and (2) Consorcio Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CB21/06/00103; to FM-T).
LinkOut - more resources
Full Text Sources
